Pharmaceutical company Ipsen will commence a Phase II, proof-of-concept study of tasquinimod in four different cancer indications.
The study is designed to assess the safety and efficacy of tasquinimod in advanced or metastatic hepato-cellular, ovarian, renal cell and gastric carcinomas in patients already treated with standard anti-tumor therapies.
Ipsen R&D executive vice president and chief scientific officer Claude Bertrand said tasquinimod should be assessed beyond prostate cancer due to its unique mode of action.
"We hope that this innovative, proof-of-concept study in oncology will generate data on tasquinimod’s biological and clinical activity and safety profile supporting further clinical development in high unmet medical need diseases," Bertrand said.
The multi-centre, open-label, early stopping design, proof of concept study will measure the clinical activity of Tasquinimod by the section of patients with progression free survival at pre-defined time-points.
Tasquinimod’s immunomodulatory and anti-angiogeneic properties are applicable in addressing unmet medical need in a range of carcinomas.
Under a co-development agreement signed in April 2011, Ipsen gained exclusive rights from Active Biotech to commercialise tasquinimod worldwide, except for North and South America and Japan where Active Biotech preserved all commercial and marketing rights.